Adults treated with medication for chronic hypertension present before or during the first 20 weeks of pregnancy had fewer adverse pregnancy outcomes compared to adults who did not receive antihypertensive treatment.
Patients who have chronic kidney disease and pulmonary hypertension are at a greater risk for a variety of adverse outcomes, according to new research.
In certain patients, measurements of pulmonary artery (PA) distensibility are more effective at detecting pulmonary hypertension due to left heart disease than measurements of PA dilatation.
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreIn obstructive sleep apnea patients with high blood pressure resistant to treatment, the more severe their OSA, the higher their blood pressure.
Read MoreScientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read More
SoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read More
Patients at greatest risk of dying from PAH may be identified through cardiac MRI and the information the noninvasive scan provides about the functional level of the heart’s right ventricle.
Read More
In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read More
Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More
Development of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.
Read More
Research reports that male sex may be predictive of right ventricular dysfunction in some pulmonary hypertension patients.
Read More
RTs may find it difficult to choose between available inhaled pulmonary vasodilators (IPVs)—inhaled nitric oxide or nebulized epoprostenol—to treat pulmonary hypertension.
Read More